Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study

Article type: Research Article

Keywords: allergic diseases, mendelian randomization, protein, targeted therapy

Authors: Hui Wang, Jianyu Pang, Yuguan Zhou, Qi Qi, Yuheng Tang, Samina Gul, Miaomiao Sheng, Juhua Dan, Wenru Tang ⚬

Affiliations: Laboratory of Molecular Genetics of Aging & Tumor Medicine School Kunming University of Science and Technology Kunming Yunnan China

License: © 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. CC BY 4.0 This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Article links: DOI: 10.1002/clt2.12350  |  PubMed: 38573314  |  PMC: PMC10994001

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (1.3 MB)

INTRODUCTION

Allergic diseases usually refer to a group of heterogeneous diseases mainly caused by mast cell or eosinophil activation, including atopic dermatitis (AD), allergic rhinitis (AR) and asthma.ref. clt212350-bib-0001 The pathogenesis of allergic diseases remains unclear, likely arising from the complex interplay of various factors such as genetics, environment, microbiota, and immune system function. However, these allergic diseases share common underlying mechanisms, partially mediated by immunoglobulin E.ref. clt212350-bib-0001 The incidence of asthma and other allergic diseases (such as AR and AD) has increased significantly in recent decades. These conditions affect approximately one‐fifth of the global population,ref. clt212350-bib-0002 posing a substantial burden worldwide. Asthma is a chronic inflammatory respiratory disease, which is characterized by increased sensitivity and respiratory obstruction. Its symptoms include dyspnea, coughing, chest tightness and wheezing. Severe asthma accounts for 5%–10% of the asthmatic population in the world. Unfortunately, about 3.6% of patients with asthma still experience poor asthma control even when receiving standard treatment.ref. clt212350-bib-0003 AD is a common inflammatory skin disease, which is characterized by recurrent eczema‐like lesions and strong itching. It affects individuals of all ages and ethnicities, causing significant psychosocial impacts on both patients and their relatives. Atopic dermatitis is the main cause of global burden of skin diseases.ref. clt212350-bib-0004 AR is a common chronic upper respiratory disease, which is characterized by nasal mucosal inflammation caused by allergens. It usually shows symptoms such as stuffy nose, runny nose, sneezing and itchy nose.ref. clt212350-bib-0005 These symptoms significantly impact the quality of life for affected individuals, imposing a substantial burden on both their families and society at large.ref. clt212350-bib-0006 Research suggests that allergic diseases (asthma, AR, and AD) coexist to a certain extent due to the presence of numerous shared genetic risk variants. These variants contribute to alterations in the expression of immune‐related genes.ref. clt212350-bib-0007 Although there are some drugs for allergic diseases, such as fluticasone,ref. clt212350-bib-0008 salmeterol,ref. clt212350-bib-0009 loratadine,ref. clt212350-bib-0010 dupilumab,ref. clt212350-bib-0011 and hydrocortisone.ref. clt212350-bib-0012 However, due to the high prevalence of allergic diseases and the drawbacks of existing treatment medications, such as significant side effects, incomplete symptom relief, and the need for long‐term maintenance therapy, research and development in the field of allergic disease medications remain urgent.

Human proteins play a crucial role in the onset and progression of diseases and represent the primary category of drug targets.ref. clt212350-bib-0013 Research indicates that proteins associated with genetic links to diseases have significantly increased chances of gaining market approval as drug targets.ref. clt212350-bib-0014 Mendelian randomlization (MR) is a genetic method that utilizes Single Nucleotide Polymorphisms (SNPs) from Genome‐Wide Association Studies (GWAS) as genetic instruments to estimate the causal association between an exposure and an outcome. Compared to traditional observational studies, MR can mitigate the impact of confounding factors. With the advancement of high‐throughput genomics and proteomics technologies in plasma, MR‐based approaches have facilitated the identification of potential therapeutic targets for various diseases.ref. clt212350-bib-0015, ref. clt212350-bib-0016 However, to date, there have been few reports on studying allergic diseases by integrating GWAS and protein quantitative trait loci (pQTL) data.

In this study, our aim was to identify plasma proteins as potential therapeutic targets for allergic diseases. The study design is illustrated in Figure 1. First, we employed GWAS data from Ferreira MA et al.ref. clt212350-bib-0007 and plasma pQTL data from Ferkingstad E et al.ref. clt212350-bib-0017 to identify potential plasma pathogenic proteins for allergic diseases using MR. Second, reverse causal association, Bayesian colocation analysis, and phenotype scanning were further employed to validate the findings. Third, we further validated our findings using two large external cohorts, namely the UK Biobank and FinnGen. Next, we constructed a protein‐protein interaction network to explore the mechanisms through which pathogenic proteins contribute to the occurrence of allergic diseases. Finally, based on the potential protein targets determined through MR and Bayesian Co‐location analysis, we conducted molecular docking to identify potential drugs for allergic diseases.

MATERIALS AND METHODS

Selection of plasma protein data

From the large‐scale protein quantitative trait loci (pQTL) study of 35,559 Icelanders, the summary statistical data related to 4907 circulating proteins were extracted.ref. clt212350-bib-0017 Proteomic analysis was performed using a multiplexed, modified aptamer‐based binding assay (SOMAscan version4). Protein levels underwent rank‐inverse normal transformation based on age and gender, and residuals were standardized through rank‐inverse normal transformation. The standardized values were treated as phenotypes in genome‐wide association analyses under the BOLT‐LMM linear mixed model. Detailed information on GWAS can be found in the original publication.ref. clt212350-bib-0017 This study included proteins with cis‐pQTLs obtained at the genome‐wide significant level (p < 5 × 10⁻⁸) in a two‐sample MR. Significant cis‐pQTLs was used for subsequent analysis.

GWAS summary data of outcome

The primary analysis utilized summary statistics from Ferreira MA et al.,ref. clt212350-bib-0007 encompassing 360,838 individuals of European ancestry (nCase = 180,129, nControl = 180,709). Further validation of the primary analysis results was conducted through external cohorts from FinnGen (R9 release, Asthma: nCase = 21,392, nControl = 210,122; AR: nCase = 11,009, nControl = 359,149; AD: nCase = 40,688, nControl = 336,589)ref. clt212350-bib-0018 and the UK Biobank (Asthma: nCase = 39,049, nControl = 298,110, AD and AR: nCase = 77,891, nControl = 258,891).ref. clt212350-bib-0019

STATISTICAL ANALYSIS

Mendelian randomization analysis and external validation

In this study, we utilized plasma proteins as the exposure, allergic diseases as the outcome, and employed the “TwoSampleMR” package (ver. 0.5.6) for MR analysis. If a specific protein has only one pQTL, the Wald ratio is employed. When two or more suitable pQTLs are available, inverse variance‐weighted MR (MR‐IVW) is applied, followed by heterogeneity analysis.ref. clt212350-bib-0020 The odds ratio of increasing the risk of allergic diseases is expressed as the standard deviation (SD) of the increase in plasma protein level.

In the primary analysis, we applied the Bonferroni correction to adjust for multiple tests. Then, we used the threshold p‐value of 0.05/1537 (p < 3.25 × 10⁻⁵) to screen the results, and the significant proteins were used for subsequent analysis. External validation of the initially identified crucial proteins was performed through MR analysis, where a p‐value <0.05 was considered significant. Finally, the estimated values of potential drug targets in FinnGen or UK Biobank were combined by the meta‐analysis of random effects.

Reversal analysis of causality

Following the same pQTLs selection criteria, we obtained 74 instrumental variables for allergic diseases. Subsequently, we performed bidirectional two‐sample univariable MR to assess potential reverse causation in our primary MR analysis. We employed five algorithms from the “TwoSampleMR” package (ver. 0.5.6), namely MR‐IVW, MR‐Egger, Weighted median, Simple mode, and Weighted mode, to estimate the effects. Additionally, Steiger filtering was conducted to ensure the directionality of the association between proteins and allergic diseases.ref. clt212350-bib-0021 The p‐value <0.05 is considered statistically significant.

Bayesian co‐localization analysis

We utilized the “coloc” package (ver. 5.1.0) for co‐localization analysis, where Bayesian co‐localization analysis is employed to assess the probability of two features sharing the same causal variable. Previous studies have indicated that Bayesian co‐localization provides posterior probabilities for five hypotheses, aiming to determine whether two traits share a single variant.ref. clt212350-bib-0022 In this study, we evaluated the posterior probabilities of Hypothesis 3 and Hypothesis 4 (PPH4). In hypothesis 3, the protein and allergic diseases are associated with the region through distinct variants, while in hypothesis 4, both the protein and allergic diseases are associated with the region through shared variants. The criterion for determining co‐localization between protein and allergic diseases was based on the Bayesian co‐localization analysis, specifically when the PPH4 posterior probability exceeded 0.8.ref. clt212350-bib-0023

Phenotype screening

We employed the “PhenoScanner” package (ver. 1.0)ref. clt212350-bib-0024 for phenotype screening, searching through previous GWAS to unveil associations of identified pQTLs with other traits. pQTL meeting the following criteria were considered pleiotropic: (i) the association is significant at a genome‐wide level (p < 5 × 10⁻⁸); (ii) the GWAS was conducted in populations of European ancestry; (iii) the SNP is associated with any known risk factors for allergic diseases, including metabolic traits, proteins, or clinical features.

Protein‐protein interaction network analysis

To investigate potential interactions among identified proteins, we utilize the STRING database (https://string‐db.org/) to construct a Protein‐Protein Interaction (PPI) network. Subsequently, we conduct a visual analysis of the Protein‐Protein Interaction (PPI) network based on STRING using Cytoscape software (ver. 3.9.1).

Targeted drug screening

After identifying potential drug targets based on MR and Bayesian co‐localization analyses, we utilized Autodock (Linux, ver. 4.2) for molecular docking to investigate the interaction of small molecular compounds with potential drug target genes. First, we obtained the catalog of small molecules interacting with potential drug target genes from the CTD database (https://ctdbase.org) and downloaded the structures of these small molecules from the PubChem database (https://pubchem.ncbi.nlm.nih.gov). Subsequently, we retrieved the biomacromolecule structure of the potential drug target gene from the UniProt database (https://www.uniprot.org). Finally, following the standard docking procedure, biological macromolecules and small molecular compounds were automatically docked, and those small molecular compounds demonstrating stable binding with biological macromolecules exhibited lower binding energy. Additionally, the results were visualized using PyMol (ver. 2.6, open source).

RESULTS

Protein‐wide mendelian randomization for screening causal proteins in allergic diseases

At Bonferroni significance (p < 3.25 × 10⁻⁵), the MR analysis revealed 11 significantly associated protein‐allergic diseases pairs (Table 1, Figure 2), namely, Interleukin‐6 receptor (IL6R), Interleukin‐1 receptor (IL1R1), TNF alpha induced protein 3 (TNFAIP3), Erb‐b2 receptor tyrosine kinase 3 (ERBB3), Inositol‐trisphosphate 3‐kinase A (ITPKA), Interleukin 1 receptor‐like 1 (IL1RL1), Toll‐like receptor 1 (TLR1), Kynureninase (KYNU), Layilin (LAYN), LDL receptor related protein 11 (LRP11), Interleukin 1 receptor like 2 (IL1RL2). Specifically, elevated levels of TNFAIP3, ERBB3, TLR1, and IL1RL2 proteins were associated with a reduced risk of allergic diseases, yielding corresponding odds ratios of 0.82 (0.76–0.88), 0.74 (0.66–0.82), 0.49 (0.45–0.55), and 0.81 (0.75–0.87), respectively. Conversely, increased levels of IL6R, IL1R1, ITPKA, IL1RL1, KYNU, LAYN, and LRP11 proteins were linked to an elevated risk of allergic diseases, with corresponding odds ratios of 1.04 (1.03–1.05), 1.25 (1.18–1.34), 1.48 (1.25–1.75), 1.14 (1.11–1.18), 1.09 (1.05–1.12), 1.96 (1.56–2.47), and 1.05 (1.03–1.07), respectively. Preliminary MR analysis showed no heterogeneity of pathogenic proteins of allergic diseases (Table S1).

Sensitivity analysis for allergic diseases causal proteins

Following sensitivity analysis and MR analysis, we identified two proteins among the 11 significant ones as potential drug targets for allergic diseases, namely LAYN and TNFAIP3. Firstly, we conducted reverse MR analysis, and the results indicated that there were no causal effects of allergic diseases on the levels of 10 identified proteins, including IL6R, IL1R1, TNFAIP3, ERBB3, ITPKA, IL1RL1, TLR1, KYNU, LAYN and LRP11. Nonetheless, allergic diseases exert a causal effect on the protein level of IL1RL2, suggesting that IL1RL2 could serve as a potential biomarker for allergic diseases. Steiger filtering further ensured the directionality (Table 2 and Figure S1). Next, we performed Bayesian co‐localization analysis, and the results suggested that LAYN (coloc.abf‐PPH4 = 0.819) and TNFAIP3 (coloc.abf‐PPH4 = 0.930) share the same variant with allergic diseases (Table 2 and Figure S2). Finally, phenotypic scanning revealed some correlations, such as the correlation between IL6R and asthma, AD and eczema, the correlation between TNFAIP3 and some autoimmune diseases such as rheumatoid arthritis and Systemic lupus erythematosus (SLE), the correlation between ITPKA and the abundance of some immune cells, the correlation between ERBB3 and body mass index and thyroid dysfunction, the correlation between IL1RL1 and asthma and autoimmune diseases such as Crohn’s disease and inflammatory bowel disease, and the correlation between TLR1 and allergic diseases such as asthma, hay fever and eczema (Table 2 and Table S2).

External validation of potential drug targets for allergic diseases

To validate the accuracy of the preliminary MR analysis, we conducted validation in two external cohorts, FinnGen and UK Biobank. In the meta‐analysis of the FinnGen cohort, seven proteins showed significant associations, and the odds ratios (95% confidence intervals, CI) for allergic diseases per standard deviation increase in genetically predicted protein levels were as follows: TNFAIP3 0.87 (0.78–0.96), IL1RL2 0.85 (0.80–0.92), IL1R1 1.14 (1.06–1.21), IL6R 1.03 (1.01–1.04), KYNU 1.04 (1.00–1.07), LRP11 1.04 (1.02–1.06) and ITPKA 1.74 (1.48–2.04). In the meta‐analysis of the UK Biobank cohort, 10 proteins exhibited significant associations. The odds ratios (95% confidence intervals, CI) for allergic diseases per standard deviation increase in genetically predicted protein levels were as follows: TNFAIP3 0.97 (0.95–0.99), LAYN 1.09 (1.01–1.18), TLR1 0.89 (0.79–1.00), IL1RL2 0.96 (0.95–0.97), IL1R1 1.04 (1.02–1.06), IL1RL1 1.03 (1.02–1.03), IL6R 1.01 (1.00–1.01), KYNU 1.01 (1.00–1.02), ITPKA 1.07 (1.03–1.11) and ERBB3 0.95 (0.93–0.97) (Figure 3).

Protein‐protein interaction and potential target drug therapy

The protein‐protein interaction analysis revealed interactions among the identified potential causal proteins. Notably, interactions were observed between TNFAIP3 and IL1R1 as well as TLR1. Additionally, interactions were found among IL1RL1, IL1RL2, IL1R1, and IL6R. Moreover, interactions were noted between IL1R1 and TLR1 as well as IL6R. They mainly participate in regulating biological pathways such as inflammatory responses and immune reactions (Figure S3). Through MR and Bayesian colocalization analysis, we identified TNFAIP3 and LAYN as potential drug targets for allergic diseases. An increase in TNFAIP3 protein levels was negatively correlated with the risk of allergic diseases, whereas an increase in LAYN protein levels was positively correlated with the risk of allergic diseases. Therefore, we screened small molecular compounds from the CTD database that can increase TNFAIP3 expression and decrease LAYN expression, and performed molecular docking using Autodock. Four small molecular compounds can dock with TNFAIP3 increasing its expression. Four small molecular compounds can dock with LAYN decreasing its expression. The docking results of small molecular compounds with TNFAIP3 are shown in Figure 4A–D. The docking results of small molecular compounds with LAYN are shown in Figure 4E–H. Their simulated binding energies are −13.08 (kcal/mol), −9.39 (kcal/mol), −6.57 (kcal/mol), −6.44 (kcal/mol), −7.89(kcal/mol), −6.39(kcal/mol), −7.28 (kcal/mol) and −6.81 (kcal/mol), respectively (Table S3). In summary, we have identified four small molecular compounds that can upregulate TNFAIP3 expression and four that can downregulate LAYN expression, providing insights for targeted therapy of allergic diseases.

DISCUSSION

In this study, we used a two‐sample MR method to explore causal proteins related to allergic diseases. Ten potential drug targets for allergic diseases were identified, comprising TNFAIP3, LAYN, TLR1, IL1R1, IL1RL1, IL6R, KYNU, ITPKA, LRP11 and ERBB3. IL1RL2 was identified as a potential biomarker for allergic diseases. Bayesian co‐location analysis showed that TNFAIP3 and LAYN may have the same variants as allergic diseases. To validate the accuracy of the primary MR analysis results, we conducted external validation using the FinnGen and UK Biobank cohorts. The results demonstrated a significant association of TNFAIP3, IL1RL2, IL1R1, IL6R, KYNU, and ITPKA with allergic diseases in both cohorts, further supporting the reliability of the potential drug targets identified in this study.

The occurrence of diseases is a complex process primarily attributed to alterations in genes and proteins. Changes in genes lead to structural modifications in proteins, ultimately resulting in the onset of diseases. Consequently, alterations in proteins are closely linked to the occurrence of diseases. The human proteome serves as a key target for disease therapy. Therefore, to identify novel drug targets for allergic diseases, we employed a comprehensive approach integrating MR and Bayesian colocalization to assess the causal proteins associated with allergic diseases.ref. clt212350-bib-0025 First of all, in order to eliminate the influence of reverse causality, we conducted a bidirectional MR analysis. Bidirectional MR analysis did not reveal any causal effects of allergic diseases on the levels of 10 identified proteins. Further validation of the directionality of causation was performed through Steiger filtering. Second, to mitigate the impact of horizontal pleiotropy, we exclusively utilized cis‐pQTLs as instrumental variables. This choice was made because these loci directly influence the transcription and translation processes of the associated genes.ref. clt212350-bib-0026 Next, we employed Bayesian colocalization analysis to eliminate biases caused by linkage disequilibrium. With a critical threshold of 0.8 for the posterior probability 4, two proteins identified through MR analysis may share the same variant with allergic diseases.ref. clt212350-bib-0027 Finally, through phenotypic screening, we discovered that the protein targets identified by MR were associated with various traits. However, these associations are insufficient to fully elucidate the relationship between proteins and allergic diseases. This study suggests that TNFAIP3 and LAYN may serve as potential drug targets for allergic diseases.

Allergic diseases (asthma, AR, and AD) often coexist in the same individual,ref. clt212350-bib-0028 partially due to shared genetic origins.ref. clt212350-bib-0029, ref. clt212350-bib-0030, ref. clt212350-bib-0031 While many targets for allergic diseases (asthma, AR, and AD) have been discovered in recent years, developing new drugs or repurposing existing ones for the treatment of these diseases remains challenging. Ferreira MA et al.ref. clt212350-bib-0007 identified drug targets for a range of allergic diseases based on GWAS and eQTL analyses, while our study utilized pQTLs to identify potential drug targets for allergic diseases. Therefore, our study is an important addition to the research by Ferreira MA et al. in identifying drug targets for allergic diseases, which is crucial for the development of market‐approved drugs.

TNFAIP3 (Tumor Necrosis Factor Alpha‐Inducible Protein 3) is a gene that encodes the TNFAIP3 (A20) protein, serving as a critical anti‐inflammatory regulatory factor.ref. clt212350-bib-0032 It plays a significant role in anti‐inflammatory responses,ref. clt212350-bib-0033 autoimmune diseases,ref. clt212350-bib-0034, ref. clt212350-bib-0035 and the development of tumors.ref. clt212350-bib-0036, ref. clt212350-bib-0037 Specifically, TNFAIP3 regulates the anti‐inflammatory process of the immune system by inhibiting the NF‐κB signaling pathway and reducing the production of inflammatory factors.ref. clt212350-bib-0038 Abnormal expression or mutation of TNFAIP3 is closely related to the pathogenesis of autoimmune diseases.ref. clt212350-bib-0039 The relationship between TNFAIP3 and tumors is complex and multifaceted. On one hand, TNFAIP3 can reduce the progression of inflammation‐related tumors. On the other hand, the abnormal expression of TNFAIP3 may promote the development of tumor.ref. clt212350-bib-0040 However, it remains unclear whether TNFAIP3 plays a role in allergic diseases. Based on MR and Bayesian co‐location analysis, we identified TNFAIP3 as a potential drug target for allergic diseases. Besides, through phenotype screening, we identified an association between TNFAIP3 (rs5029937) and various autoimmune diseases, such as rheumatoid arthritis and SLE, consistent with previous research. Finally, our protein interaction network analysis shows that there are interactions between TNFAIP3 and TLR1 and/or IL1R1. This suggests that TNFAIP3 may exert its associated functions through interactions with TLR1 and/or IL1R1.

TLR1 Toll‐like Receptor 1 is a member of the Toll‐like receptor family and plays a crucial role in the immune system.ref. clt212350-bib-0041 Previous research has demonstrated that TLR1 plays a crucial role in the occurrence and development of various diseases, including infectious diseases,ref. clt212350-bib-0042 autoimmune diseases,ref. clt212350-bib-0043 and cancer.ref. clt212350-bib-0044 Specifically, TLR1 activates downstream signaling pathways, primarily involving NF‐κB, MAPK, and IRF, through interactions with co‐receptors and adapter.ref. clt212350-bib-0045 The activation of these signaling pathways promotes the inflammatory response and the activation of immune cell, which plays a vital role in anti‐infectionref. clt212350-bib-0046 and tumor immune responses.ref. clt212350-bib-0044 However, it is not clear whether TLR1 plays a role in allergic diseases and the possible mechanisms involved. In this study, through phenotype screening, we found that TLR1 (rs5743618) is associated with allergic diseases, breast cancer, and the positivity rate of Helicobacter pylori in serum. Therefore, we think that TLR1 may be expected to be a therapeutic target for allergic diseases.

IL1R1 is a membrane‐bound protein, which can also be cleaved into a soluble circulating form by matrix metalloproteinases. Both the membrane‐bound and soluble forms of IL1R1 have biological activity, which regulates the inflammatory response by activating and antagonizing cytokine activity.ref. clt212350-bib-0047, ref. clt212350-bib-0048 Studies have demonstrated the association of IL1R1 with autoimmune diseases, including rheumatoid arthritis,ref. clt212350-bib-0049 as well as cancers such as breast cancerref. clt212350-bib-0050 and colorectal cancer,ref. clt212350-bib-0051 along with inflammatory diseases like inflammatory bowel disease.ref. clt212350-bib-0052 First of all, our research shows that the expression level of IL1R1 protein is related to the occurrence of allergic diseases. Next, we have been further verified in two large independent external cohorts, providing further evidence for IL1R1 as a potential target for allergic diseases. Finally, protein‐protein interaction network analysis reveals interactions between IL1R1 and TLR1, TNFAIP3, IL6R, and IL1RL1. In conclusion, IL1R1 could be a potential therapeutic target for allergic diseases.

LAYN, a widely expressed integral membrane hyaluronan receptor, encodes Layilin, a membrane glycoprotein featuring the structural domain of C‐type lectin.ref. clt212350-bib-0053 Prior studies have indicated that LAYN is associated with cellular senescence, expressed in specific cells and organs, and plays a crucial role in regulating motility, cell adhesion, and migration.ref. clt212350-bib-0054, ref. clt212350-bib-0055 Furthermore, LAYN plays a role in cancer development and enhances anti‐tumor immunity by promoting the activation of integrins.ref. clt212350-bib-0056 In this study, we identified LAYN as a potential drug target for allergic diseases through MR and Bayesian co‐location analysis.

Our research shows that TNFAIP3 and LAYN are potential drug targets for allergic diseases. The elevation of TNFAIP3 protein levels is associated with a reduced risk of allergic diseases, whereas the increase in LAYN protein levels is correlated with an elevated risk of allergic diseases. Therefore, we screened four small molecular compounds from the CTD database that can downregulate the expression levels of LAYN, including dexamethasone, dronabinol, ethinylestradiol, and calcitriol. Their simulated binding energies are −7.89(kcal/mol), −6.39(kcal/mol), −7.28 (kcal/mol), −6.81 (kcal/mol). Additionally, four small molecular compounds that elevate TNFAIP3 expression levels were identified, including cyclosporine, vincristine, Withaferin A (WA), and Ursodeoxycholic Acid (UDCA). Their simulated binding energies are −13.08 (kcal/mol), −9.39 (kcal/mol), −6.57 (kcal/mol), −6.44 (kcal/mol). Molecular docking studies show that these small molecules can effectively and stably bind TNFAIP3 and/or LAYN.ref. clt212350-bib-0057 Dexamethasone is a synthetic corticosteroid hormone that has been extensively utilized in the treatment of various conditions, including autoimmune diseases, allergies, eye disorders, cancer, and more recently COVID‐19.ref. clt212350-bib-0058 Dronabinol is a synthetic cannabinoid medication, with its active ingredient being Δ9‐tetrahydrocannabinol (THC). It has been approved and widely utilized for alleviating nausea and vomiting in chemotherapy patients.ref. clt212350-bib-0059 Ethinyl Estradiol is a potent synthetic estrogen widely employed in oral contraceptives and also utilized in the treatment of breast cancer and prostate cancer.ref. clt212350-bib-0060 Calcitriol, an active form of vitamin D commonly referred to as vitamin D3, plays a significant role in maintaining bone health and in the preventionref. clt212350-bib-0061 and treatment of cancer.ref. clt212350-bib-0062 Cyclosporine is an immunosuppressive agent that has demonstrated effective therapeutic outcomes in the treatment of conditions such as psoriasis, hallopeau continuous limb dermatitis, necrotizing pyoderma, lichen planus, chronic lichenoid pityriasis, Behçet’s disease, and alopecia areata.ref. clt212350-bib-0063 Vincristine belongs to the ergot alkaloid family and is typically utilized in the treatment of various types of cancer, including leukemiaref. clt212350-bib-0064 and lymphoma.ref. clt212350-bib-0065 WA is a pivotal drug with diverse mechanisms and extensive pharmacological characteristics. It possesses anticancer, anti‐inflammatory, anti‐herpes, anti‐fibrosis, anti‐platelet, fibrinolytic, immunosuppressive, anti‐pigmentation, anti‐parasite, and healing potential.ref. clt212350-bib-0066 UDCA is a natural bile acid used clinically for the treatment of conditions associated with bile stasis.ref. clt212350-bib-0067

Our research has some limitations. First of all, although we have studied the correlation between plasma protein level and the risk of allergic diseases (asthma, AR and AD) through genetic method, more clinical research is needed to further verify our research. In future research, it is imperative to incorporate additional clinical research to assess the impact of plasma proteins on the susceptibility to allergic diseases. Secondly, our study was conducted in populations of European descent to minimize population stratification biases. However, due to the variability in ethnic backgrounds, our study may not be generalizable to other ancestral populations.ref. clt212350-bib-0015, ref. clt212350-bib-0068, ref. clt212350-bib-0069 When we have more GWAS data on allergic diseases from additional ancestral backgrounds, we plan to conduct supplementary studies. This will enable us to further explore our research findings and facilitate the translation of our findings into clinical applications. Thirdly, we employed stringent selection criteria, utilizing a strict p‐value threshold (p < 5 × 10⁻⁸) and cis‐acting pQTLs as instrumental variables, which also constrained the applicability of some analyses, including alternative MR algorithms, heterogeneity testing, and pleiotropy testing. However, through the calculation of F‐statistics, we observed that the F‐statistics for the instrumental variables we screened were all greater than 10. F‐statistics greater than 10 exclude the influence of weak instrumental variables. Fourth, asthma is a heterogeneous disease with several subtypes (allergic and non‐allergic) and has a variable genetic background.ref. clt212350-bib-0070 In this study, we employed a genome‐wide association study (GWAS) to identify proteins associated with the risk of allergic diseases (asthma, AR and AD). However, due to the heterogeneity and variable genetic background of allergic diseases, it is necessary to combine various methods (family research, in‐depth sequencing, epigenetics, population stratification, functional research and clinical research) to deeply understand the pathogenesis, subtypes and individual differences. Finally, we employed Protein‐Protein Interaction (PPI) analysis to examine the interactions between proteins and utilized molecular docking to identify potential drug candidates. However, the findings from the PPI analysis and molecular docking are preliminary, requiring further validation in future research.

CONCLUSION

In summary, our comprehensive analysis indicates a causal relationship between genetically determined circulating levels of TNFAIP3, LAYN, IL6R, TLR1, IL1R1, IL1RL2, ERBB3, LRP11, KYNU, ITPKA, and IL1RL1 and the risk of allergic diseases. The identified proteins may serve as attractive drug targets/biomarker for allergic diseases, particularly TNFAIP3 and LAYN. Further research is warranted to explore the roles of these candidate proteins in allergic diseases.

AUTHOR CONTRIBUTIONS

Hui Wang: Concept, Manuscript writing and design; Wenru Tang, Juhua Dan and Miaomiao Sheng: Administrative support; Qi Qi, Y Tang, Yuheng Tang and Samina Gul: Collection of data; Hui Wang and Jianyu Pang: Data analysis; All authors: Approved the final manuscript.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no competing interests in this section.

CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

References

1. Allergy: mechanistic insights into new methods of prevention and therapy.. Sci Transl Med., 2023. [DOI | PubMed]
2. The atopic March: progression from atopic dermatitis to allergic rhinitis and asthma.. J Clin Cell Immunol., 2014. [DOI]
3. Management of severe asthma: a European respiratory society/American thoracic society guideline.. Eur Respir J., 2020. [DOI | PubMed]
4. Atopic dermatitis.. Lancet., 2020. [DOI | PubMed]
5. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis.. J Allergy Clin Immunol., 2001. [DOI | PubMed]
6. Brain response in allergic rhinitis: profile and proposal.. J Neurosci Res., 2023. [DOI | PubMed]
7. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology.. Nat Genet., 2017. [DOI | PubMed]
8. Inhaled formoterol‐fluticasone single inhaler therapy in asthma: real‐world efficacy, budget impact, and potential to improve adherence.. Can Respir J., 2020. [DOI | PubMed]
9. Salmeterol in the treatment of chronic asthma.. Am Fam Physician., 1997. [PubMed]
10. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders.. Drugs., 1994. [DOI | PubMed]
11. Dupilumab for treatment of atopic dermatitis.. Expet Rev Clin Pharmacol., 2018. [DOI]
12. Efficacy of topical application of human breast milk on atopic eczema healing among infants: a randomized clinical trial.. Int J Dermatol., 2015. [DOI | PubMed]
13. Phenome‐wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.. Nat Genet., 2020. [DOI | PubMed]
14. The support of human genetic evidence for approved drug indications.. Nat Genet., 2015. [DOI | PubMed]
15. Novel drug targets for ischemic stroke identified through mendelian randomization analysis of the blood proteome.. Circulation., 2019. [DOI | PubMed]
16. Plasma proteins and onset of type 2 diabetes and diabetic complications: proteome‐wide Mendelian randomization and colocalization analyses.. Cell Rep Med., 2023. [DOI | PubMed]
17. Large‐scale integration of the plasma proteome with genetics and disease.. Nat Genet., 2021. [DOI | PubMed]
18. FinnGen provides genetic insights from a well‐phenotyped isolated population.. Nature., 2023. [DOI | PubMed]
19. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.. PLoS Med., 2015. [DOI | PubMed]
20. Identifying causal genes for stroke via integrating the proteome and transcriptome from brain and blood.. J Transl Med., 2022. [DOI | PubMed]
21. Orienting the causal relationship between imprecisely measured traits using GWAS summary data.. PLoS Genet., 2017. [DOI | PubMed]
22. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease.. PLoS Genet., 2017. [DOI | PubMed]
23. Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood.. Mol Psychiatr., 2021. [DOI]
24. PhenoScanner V2: an expanded tool for searching human genotype‐phenotype associations.. Bioinformatics., 2019. [DOI | PubMed]
25. Integrating Mendelian randomization and multiple‐trait colocalization to uncover cell‐specific inflammatory drivers of autoimmune and atopic disease.. Hum Mol Genet., 2019. [DOI | PubMed]
26. From expression QTLs to personalized transcriptomics.. Nat Rev Genet., 2011. [DOI | PubMed]
27. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics.. PLoS Genet., 2014. [DOI | PubMed]
28. Comorbidity of eczema, rhinitis, and asthma in IgE‐sensitised and non‐IgE‐sensitised children in MeDALL: a population‐based cohort study.. Lancet Respir Med., 2014. [DOI | PubMed]
29. Findings on the atopic triad from a Danish twin registry.. Int J Tubercul Lung Dis., 2006
30. Genetics of parentally reported asthma, eczema and rhinitis in 5‐yr‐old twins.. Eur Respir J., 2007. [DOI | PubMed]
31. Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance‐components analysis.. Nat Genet., 2015. [DOI | PubMed]
32. Haploinsufficiency of A20 (HA20): updates on the genetics, phenotype, pathogenesis and treatment.. World J Pediatr WJP., 2020. [DOI | PubMed]
33. Regulators of A20 (TNFAIP3): new drug‐able targets in inflammation.. Am J Physiol Lung Cell Mol Physiol., 2019. [DOI | PubMed]
34. Single nucleotide polymorphisms at the TNFAIP3/A20 locus and susceptibility/resistance to inflammatory and autoimmune diseases.. Adv Exp Med Biol., 2014. [DOI | PubMed]
35. The ubiquitin‐editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.. Trends Immunol., 2009. [DOI | PubMed]
36. TNFAIP3 is required for FGFR1 activation‐promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.. Breast Cancer Res., 2018. [DOI | PubMed]
37. TNFAIP3 overexpression is an independent factor for poor survival in esophageal squamous cell carcinoma.. Int J Oncol., 2017. [DOI | PubMed]
38. Inhibition of NF‐kappaB signaling by A20 through disruption of ubiquitin enzyme complexes.. Science., 2010. [DOI | PubMed]
39. Roles of A20 in autoimmune diseases.. Immunol Res., 2016. [DOI | PubMed]
40. The dual roles of A20 in cancer.. Cancer Lett., 2021. [DOI | PubMed]
41. The assessment of TLR1 gene polymorphism association with the risk of allergic rhinitis in the Chinese han population from Northern China.. J Asthma Allergy., 2023. [DOI | PubMed]
42. Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and Candida albicans elimination.. Gut Pathog., 2017. [DOI | PubMed]
43. SIX1 attenuates inflammation and rheumatoid arthritis by silencing MyD88‐dependent TLR1/2 signaling.. Int Immunopharm., 2022. [DOI]
44. Design, synthesis, and structure‐activity relationship of N‐Aryl‐N’‐(thiophen‐2‐yl)thiourea derivatives as novel and specific human TLR1/2 agonists for potential cancer immunotherapy.. J Med Chem., 2021. [DOI | PubMed]
45. TLR1/2 orchestrate human plasmacytoid predendritic cell response to gram+ bacteria.. PLoS Biol., 2019. [DOI | PubMed]
46. Toll‐like receptors (TLRs) in innate immune defense against Staphylococcus aureus.. Int J Artif Organs., 2011. [DOI | PubMed]
47. Interleukin‐1 receptor type 1 is a substrate for gamma‐secretase‐dependent regulated intramembrane proteolysis.. J Biol Chem., 2009. [DOI | PubMed]
48. Structural basis of IL‐1 family cytokine signaling.. Front Immunol., 2019. [DOI | PubMed]
49. The impacts of IL1R1 and IL1R2 genetic variants on rheumatoid arthritis risk in the Chinese han population: a case‐control study.. Int J Gen Med., 2021. [DOI | PubMed]
50. The IL1β‐IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer‐associated fibroblasts (CAFs).. J Exp Clin Cancer Res: CR., 2020. [DOI | PubMed]
51. IL1R1+ cancer‐associated fibroblasts drive tumor development and immunosuppression in colorectal cancer.. Nat Commun., 2023. [DOI | PubMed]
52. Associations between genetic polymorphisms in IL‐33, IL1R1 and risk for inflammatory bowel disease.. PLoS One., 2013. [DOI | PubMed]
53. Molecular cloning and characterization of human chondrolectin, a novel type I transmembrane protein homologous to C‐type lectins.. Genomics., 2002. [DOI | PubMed]
54. An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence.. BMC Genom., 2011. [DOI]
55. Layilin, a novel integral membrane protein, is a hyaluronan receptor.. Mol Biol Cell., 2001. [DOI | PubMed]
56. Layilin augments integrin activation to promote antitumor immunity.. J Exp Med., 2020. [DOI]
57. Single‐cell and bulk RNA‐sequencing analysis to predict the role and clinical value of CD36 in lung squamous cell carcinoma.. Heliyon., 2023. [DOI | PubMed]
58. Dexamethasone: insights into pharmacological aspects, therapeutic mechanisms, and delivery systems.. ACS Biomater Sci Eng., 2022. [DOI | PubMed]
59. Cannabinoids: therapeutic use in clinical practice.. Int J Mol Sci., 2022. [DOI | PubMed]
60. Toxicology and carcinogenesis study of ethinyl estradiol (CAS No. 57‐63‐6) in Sprague‐Dawley rats (feed study).. Natl Toxicol Progr Tech Rep., 2010
61. Management of osteoporosis with calcitriol in elderly Chinese patients: a systematic review.. Clin Interv Aging., 2014. [DOI | PubMed]
62. The mechanism of calcitriol in cancer prevention and treatment.. Curr Med Chem., 2013. [DOI | PubMed]
63. A review and update of the clinical uses of cyclosporine in dermatology.. Dermatol Clin., 1991. [DOI | PubMed]
64. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.. J Hematol Oncol., 2015. [DOI | PubMed]
65. Treatment of advanced non‐Hodgkin’s lymphoma with vincristine infusion.. Cancer., 1984. [DOI | PubMed]
66. Withaferin A: from ancient remedy to potential drug candidate.. Molecules., 2021. [DOI | PubMed]
67. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.. Clin Liver Dis., 2004. [DOI | PubMed]
68. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.. Brain : J Neurol., 2023. [DOI]
69. Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study.. J Transl Med., 2023. [DOI | PubMed]
70. Gene polymorphisms in asthma: a narrative review.. Ann Transl Med., 2022. [DOI | PubMed]